A drug is used alone or with other drugs to treat certain types of colorectal cancer that have spread to other parts of the body. It is used in patients whose cancer has not yet been treated or whose cancer got worse after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer.
ABX-EGF binds to a protein called epidermal growth factor receptor (EGFR), which is found on some normal cells and some types of cancer cells. Blocking this protein can help prevent cancer cells from growing. ABX-EGF is a type of monoclonal antibody. Also called panitumumab and Vectibix.
A clinical trial examining the safety and efficacy of ABX-EGF when given to prostate cancer patients with or without tumors in other parts of the body.
Patients will be treated for a maximum of 48 doses (6 treatment cycles; 8 doses per cycle) or until there is evidence of disease progression.
Listed below are anti-ABC antibodies from various vendors. ABC is an alias for the human ABCB6 gene or ‘member 6 of subfamily B of the ATP-binding cassette (Langereis blood group).
The 842 amino acid protein is a member of the ABC transporter superfamily, ABCB family, heavy metal importers subfamily (TC 3.A.1.210). Cellular localization is expected to be mitochondrial and membrane-associated. Please refer to the vendor page for important antibody details such as target specificity and designated applications.
The Red Blood Cell Antibody Screen looks for circulating blood antibodies directed against red blood cells (red blood cells). The main reason a person may have antibodies to red blood cells circulating in the blood is that the person has been exposed, through a blood transfusion or during pregnancy, to red blood cells other than their own (red blood cells strangers). These antibodies have the potential to cause harm if a person receives a transfusion of red blood cells that the antibodies can attack or if a pregnant woman has antibodies that target her developing baby’s red blood cells.
Red blood cells normally have structures on their surface called antigens. People have their own individual set of antigens on their red blood cells, determined by inheritance from their parents. The main antigens or surface identifiers on human red blood cells are the O, A, and B antigens, and a person’s blood is grouped into an A, B, AB, or O blood type based on the presence or absence of these antigens.
Another important surface antigen is the Rh factor, also called the D antigen. If it is present on a person’s red blood cells, that person’s blood type is Rh + (positive); if absent, the blood is Rh- (negative). (For more information on these antigens, see the article on blood type.) In addition, there are many other types of red blood cell antigens that form lesser-known blood groups, such as the Kell, Lewis, and Kidd blood groups.
There are a few reasons why someone may make antibodies against red blood cell antigens.
After blood transfusions: Antibodies directed against red blood cell antigens A and B are naturally occurring; we produce them without having to be exposed to antigens. Before receiving a blood transfusion, a person’s ABO group and Rh type are compared to that of the donor’s blood to prevent a serious transfusion reaction from occurring.
That is, the donor’s blood must be compatible with that of the recipient so that the antibodies do not react and destroy the donor’s blood cells. If someone receives a blood transfusion, the person’s body can also recognize other red blood cell antigens of other blood groups (such as Kell or Kidd) that the person is not foreign to. The receptor can produce antibodies to attack these foreign antigens. People who receive many transfusions make antibodies against red blood cells because they are exposed to foreign red blood cell antigens with each transfusion.
During pregnancy, with blood type incompatibility between mother and baby: a baby can inherit antigens from the father that are not found on the mother’s red blood cells. The mother may be exposed during pregnancy or at the time of delivery to foreign antigens on her baby’s red blood cells when some of the baby’s cells enter the mother’s circulation when the placenta separates. The mother may begin to produce antibodies against these foreign red cell antigens.
This can cause hemolytic disease of the newborn, which usually does not affect the first baby, but affects subsequent children when the mother’s antibodies cross the placenta, stick to the baby’s red blood cells, and hemolyze them. A red blood cell antibody test can help determine if the mother has produced red blood cell antibodies outside of the ABO blood group.
The first time a person is exposed to a foreign red blood cell antigen, by transfusion or pregnancy, the person may start to produce antibodies, but their cells usually do not have time during the first exposure to produce enough antibodies to actually destroy the red blood cells. strangers. . When the next transfusion or pregnancy occurs, the immune response may be strong enough that the transfused red blood cells or the baby’s red blood cells are produced, attached, and ruptured (hemolyzed) insufficient quantity of antibodies. Antibodies against ABO antigens are naturally occurring, so they do not require exposure to foreign red blood cells.